By admin 
CureSearch for Children’s Cancer has officially announced the appointment of John Polson, the Chairman and Managing Partner of the international law firm Fisher Phillips, to its Board of Directors, marking a significant reinforcement of the organization’s strategic leadership. This appointment comes at a pivotal juncture for the national non-profit as it seeks to scale its efforts in accelerating the development of life-saving treatments for children diagnosed with cancer. Polson, a legal veteran with more than three decades of experience in navigating complex corporate environments and international operations, joins a board composed of distinguished medical experts, business executives, and advocates dedicated to transforming the landscape of pediatric oncology.
The addition of Polson to the governing body of CureSearch is expected to provide the organization with enhanced legal oversight, strategic growth insights, and a deepened connection to the corporate philanthropic sector. As the head of Fisher Phillips, Polson manages the strategic direction of 41 offices worldwide, a role that requires a high degree of organizational precision and a forward-looking approach to global challenges. His transition into a formal leadership role within CureSearch follows years of dedicated support through his firm’s charitable initiatives, signaling a natural evolution of his commitment to the cause of ending childhood cancer.
A Career Defined by Leadership and Legal Excellence
John Polson’s professional trajectory provides a robust foundation for his new role on the CureSearch board. For over 30 years, he has specialized in labor and employment law, eventually rising to the position of Chairman and Managing Partner of Fisher Phillips. Under his stewardship, the firm has not only expanded its physical footprint across the globe but has also solidified its reputation as a premier legal institution. The firm is consistently recognized in prestigious industry rankings, including The Best Lawyers in America and The Legal 500, accolades that reflect Polson’s emphasis on excellence and ethical practice.
Beyond his administrative and legal duties, Polson has long championed the concept of corporate social responsibility. He has been instrumental in integrating philanthropic goals into the corporate culture of Fisher Phillips, ensuring that the firm’s success translates into tangible benefits for the community. His experience in managing a large-scale international organization provides him with a unique perspective on governance, risk management, and resource allocation—skills that are critical for non-profits like CureSearch that operate in the highly regulated and complex field of medical research funding.
The Evolution of a Partnership: From Philanthropy to Governance
The appointment of John Polson is the culmination of a long-standing and productive relationship between Fisher Phillips and CureSearch. The firm’s philanthropic arm, known as FP Cares, has been a significant contributor to CureSearch’s mission for several years. This partnership has been characterized by both financial support and direct engagement.
One of the most notable collaborations between the two entities was the "Notes of Hope" campaign. During this initiative, Fisher Phillips employees across its dozens of offices wrote thousands of handwritten letters to children undergoing cancer treatment. These letters were designed to provide emotional support and encouragement to families facing the grueling realities of pediatric oncology. The campaign highlighted the firm’s ability to mobilize its workforce for a common social good, a trait that CureSearch leaders have frequently commended.
In addition to the "Notes of Hope" campaign, FP Cares successfully raised $200,000 for CureSearch, funds that were directly funneled into high-impact research projects. In recognition of these sustained efforts, CureSearch previously honored Fisher Phillips with the "Champion for Cures" award. This history of collaboration ensures that Polson enters his board position with a deep understanding of the organization’s operational needs and its long-term objectives.
The Critical State of Pediatric Cancer Research
The context of Polson’s appointment is defined by the urgent need for innovation in pediatric oncology. While significant strides have been made in adult cancer treatments over the last few decades, pediatric research has historically faced a "funding gap." According to national health data, only a small fraction of federal cancer research funding is specifically allocated to childhood cancers. This disparity often leaves pediatric oncologists with outdated treatment protocols that can lead to long-term health complications for survivors.
CureSearch was founded to address this specific challenge by bypassing the traditional, often slow-moving pathways of academic research. The organization focuses on the "CureSearch Catapult," a strategy designed to fast-track the development of new drugs and therapies. By providing the necessary funding and expertise to move projects from the laboratory (preclinical stage) to clinical trials, CureSearch aims to bridge the "Valley of Death"—the phase where many promising medical discoveries stall due to a lack of resources.
The success of this model is evidenced by the organization’s current metrics. While the national average for cancer research projects successfully transitioning from preclinical stages to clinical trials sits at approximately 8%, CureSearch-funded projects boast a success rate of 60%. This nearly eight-fold increase in efficiency demonstrates the effectiveness of their targeted funding approach. Polson’s role will involve helping to maintain this momentum and identifying new avenues for institutional growth.
Strategic Objectives and Official Responses
The leadership at CureSearch has expressed high expectations for the impact Polson will have on the organization’s future. Kay Koehler, President and CEO of CureSearch for Children’s Cancer, emphasized that Polson’s ability to build strong relationships and his proven track record in social impact were primary factors in his selection.
"We are thrilled to welcome John Polson to the CureSearch Board of Directors," Koehler stated. "John’s proven leadership, deep commitment to social impact, and ability to build strong relationships will be invaluable as we continue our work to bring life-saving treatments to children with cancer. His experience and vision will help us take our mission to the next level."
In his own statement, Polson underscored the personal importance of the mission. "I am honored to join CureSearch in their fight to end childhood cancer," Polson said. "This is a cause that is very close to my heart, and I look forward to helping drive the organization’s critical work in advancing research and providing hope to children and families affected by cancer."
Polson joins a board that is tasked with the fiduciary and strategic oversight of the organization. His responsibilities will include reviewing research portfolios, approving annual budgets, and participating in the development of the organization’s multi-year strategic plans. His legal background will be particularly relevant in navigating the intellectual property and regulatory landscapes associated with pharmaceutical development.
Broader Impact and Implications for the Non-Profit Sector
The appointment of a high-profile legal leader to a medical research board reflects a growing trend in the non-profit sector toward "interdisciplinary governance." Non-profits are increasingly seeking leaders from the legal, financial, and technology sectors to complement the expertise of medical professionals. This diversity in leadership allows organizations to operate with the efficiency of a private-sector firm while maintaining their mission-driven focus.
For CureSearch, Polson’s international experience may also open doors for global collaborations. As pediatric cancer is a global health challenge, the ability to coordinate research and funding across international borders is essential. Fisher Phillips’ presence in 41 offices provides a network that could potentially be leveraged for international fundraising and awareness campaigns.
Furthermore, Polson’s appointment sends a strong signal to the corporate world about the importance of sustained engagement. By moving from a corporate donor to a board member, Polson exemplifies how business leaders can transition from passive giving to active governance, providing a blueprint for other executives looking to make a substantive impact in the charitable sector.
Looking Ahead: The Future of CureSearch
As CureSearch enters the next phase of its mission, the organization is focused on several key priorities. These include expanding the number of clinical trials available to children with rare or resistant forms of cancer, increasing the diversity of the patient populations involved in research, and advocating for policy changes that incentivize the development of pediatric-specific drugs.
The organization’s 60% success rate in advancing preclinical projects remains a cornerstone of its value proposition to donors and stakeholders. With Polson’s guidance, CureSearch aims to further refine its project selection process, ensuring that every dollar invested has the highest possible probability of reaching the bedside.
In conclusion, the appointment of John Polson to the CureSearch Board of Directors is more than a standard leadership change; it is a strategic alignment of legal expertise, corporate philanthropy, and medical advocacy. As the organization continues to outperform national averages in research development, Polson’s leadership will be instrumental in ensuring that these scientific successes are translated into accessible, life-saving treatments for children across the globe. The partnership between a leader in the legal field and a leader in pediatric research sets a promising precedent for the future of the fight against childhood cancer.
